Advanced Connection Technology (ACT), a connector manufacturer, announced in its online investor conference yesterday that while it remains optimistic about the rising demand for automotive components driven by the growth of electric and autonomous vehicles—and is actively submitting samples of robotic wire harnesses—it is now also stepping into the regenerative medicine field, with plans to develop exosome-based cancer screening applications in the future.

Currently, automotive components account for over 80% of ACT’s revenue, while 3C and medical applications each contribute about 1.5–1.6%, with the remainder coming from other healthcare-related uses. In the first half of this year, ACT’s revenue grew 16.6% year over year, with after-tax net income reaching NT$35.28 million and earnings per share of NT$0.99.

ACT stated that with the rising adoption of electric vehicles and demand for higher performance, the need for automotive connectors continues to grow. The company has a vertically integrated manufacturing advantage and has already entered the supply chains of major automakers in Europe, the U.S., and China. It is also actively submitting robotic wire harness products for client evaluation.

In response to rising labor and material costs in recent years, as well as pressures from the U.S.-China trade war, ACT noted that soaring costs have become a major challenge for manufacturers. The company has been striving to reduce material waste and inventory loss through design and production optimization, while also developing its own automated assistive devices to help customers navigate these challenges. Additionally, its ability to flexibly shift production between factories in China and Vietnam allows it to optimize profitability.

ACT is now combining its electronics expertise with regenerative medicine technologies by establishing a cloud-based alliance that integrates biomedical technologies and market capital. The company highlighted that it has capabilities in cell processing and quality analysis, and its laboratory currently focuses on cell-related contract testing services. Looking ahead, ACT plans to further develop exosome-based cancer screening applications.

Resource: 長盛跨足生醫細胞代檢，將發展外泌體癌症篩檢